AUTHORS
Ricardo Daniel Parrondo, MD, Athanasios Tsalatsanis, PhD2, Julio C Chavez, MD, MS3, Sikander Ailawadhi, MD4, Hong Qin, MD, PhD5, Ambuj Kumar, MD, MPH6, Mohamed Kharfan-Dabaja, MD7
AFFILIATIONS
1 Mayo Clinic, Jacksonville, Florida, United States
2 University of South Florida, Tampa, Florida, United States
3 Mayo Clinic, Jacksonville, Florida, United States
4 Mayo Clinic, Jacksonville, Florida, United States
5 Mayo Clinic, Jacksonville, Florida, United States
6 University of South Florida, Tampa, Florida, United States
7 Mayo Clinic, Jacksonville, Florida, United States
ABSTRACT
Background: The data surrounding the impact of mental health diagnoses (MH+) on survival outcomes in multiple myeloma (MM) is limited. MH+ have been consistently associated with poorer quality of life, greater symptom burden, increased healthcare utilization, and higher healthcare costs in patients (pts) with MM. Anti-BCMA CAR-T cell therapies have improved survival outcomes in MM pts, compared to standard of care therapies. The impact of MH+ in the BCMA- CAR-T era is unknown as these pts. may have been excluded from pivotal registrational clinical trials. Available data suggests MM pts with mental health diagnoses might be at higher risk of immune effector cell associated neurotoxicity (ICANS). To evaluate the real-world impact of MH+ on outcomes of MM pts treated with anti-BCMA CAR-Ts, we performed a retrospective cohort study using a large, multi-institutional electronic health record database.
Methods: We conducted a multicenter retrospective cohort study using the TriNetX Global Health Research Network to identify pts with relapsed/refractory MM (RRMM) who received anti-BCMA CAR-T therapy from March 1, 2021, through July 1, 2026 and had a MH+ vs. not at the time of CAR-T. Patients were selected based on MM diagnosis, MH+, and drug exposure codes. The index event was the start of the relevant study therapy. The TriNetX propensity-score matching adjusted for age at index event and gender. Key outcomes included overall survival (OS) rates at 1,2, and 5-years post-CAR-T, any grade cytokine release syndrome (CRS), any grade immune effector cell neurotoxicity syndrome (ICANS), and readmission rates. Kaplan-Meier analysis was used to estimate OS. CRS and ICANS were graded using the the established ASTCT criteria.
Results: Among 1212 pts identified, 573 were MH+ and 639 were MH- at the time of anti-BCMA CAR-T. After applying eligibility criteria and performing 1:1 propensity score matching, 525 pts that were MH+ were matched with 525 pts that were MH-, for a total of 1050 pts in the final matched cohort. 620 (59%) pts received ciltacabtagene autoleucel (cilta-cel) and 430 (41%) received idecabtagene vicleucel (ide-cel). Amongst pts that were MH+, 54.5% received cilta-cel and 45.7% received ide-cel. Amongst pts that were MH-, 63.6% received cilta-cel and 36.4% received ide-cel. Groups were balanced in terms of age (median of 64.9 years [yrs] for MH+ vs. 64.8 yrs for MH-) and gender, but amongst whites, more whites were MH+ (78.1%) vs. MH- (57.7%), p<0.001 whereas amongst blacks, more blacks were MH- (24.2%) vs. MH+ (15%), p<0.001. MH+ pts (vs MH-) were more likely to be on antidepressants (56.2% vs 15.5%, p<0.001) and on antispychotics (30.9% vs 21.5%, p<0.001) and less likely to be married 30.9% vs 40.4%, p=0.001). No differences in OS rate at 1 yr for pts who were MH- (88.6%) vs. MH+ (85.5%), p=0.31 were observed. There was a potential improved OS rate for MH- compared to MH+ pts at 3 years (72.6 vs 61.1%, p=0.06) and 5 years (67.4 vs 52.6%, p=0.05), respectively. MH+ (50.2%) pts were more likely to develop any grade CRS compared to pts who were MH (41.9%), p=0.006 as well as any grade ICANS; 20% vs. 15.5%, p=0.005, respectively. Additionally, MH+ pts had higher readmission rates at 1yr compared to MH- pts at 65.5% vs. 59.2%, respectively, p=0.03.
Conclusion: In this large real-world cohort of patients with RRMM treated with anti-BCMA CAR-T therapy, pre-existing MH diagnoses were associated with a trend towards inferior long-term OS. Patients with MH diagnoses also experienced higher rates of CRS, ICANS, and hospital readmissions. Prospective studies are warranted to better define the mechanisms underlying these associations and to determine whether targeted mental health interventions can improve CAR-T outcomes.
DISCLOSURES
Ricardo Daniel Parrondo, MD: Sanofi Aventis - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)